Analysis

The Road to
Reimbursement

Five sequential gates determine whether psychedelic-assisted therapy enters the insurance ecosystem. Each must be unlocked: clinical infrastructure first, regulatory permission second, standardized coding third, coverage policy fourth, and payment mechanics last.

The Five Gates

Infrastructure

→

Permission

→

Language

→

Policy

→

Money

	Gate	Function	Current Status
00	Gate 0 Infrastructure Clinical Delivery	Before regulatory approval or reimbursement pathways activate, the physical and operational infrastructure required to deliver psychedelic-assisted therapy must already exist. This includes clinical space, a qualified provider workforce, controlled substance compliance systems, and billing infrastructure capable of submitting emerging CPT codes. REMS certification requirements (where applicable) must be completed at the site level before any approved therapy can be administered.	Clinical spacePrivate rooms; multi-hour session capacity; continuous monitoring Provider workforcePrescriber + therapist/facilitator + clinical monitor Compliance systemsDEA protocols; REMS where applicable; adverse event procedures Payor readinessCredentialing, enrollment & contracting completed prior to approval Billing & data systemsCPT code integration; outcomes capture; claims-ready documentation
↓ unlocks regulatory activation
01	Gate 1 Permission Regulatory	Regulatory authorization is the gating mechanism. Without federal and state permission (FDA approval, DEA scheduling, prescribing authority), no billing system or insurance contract can be activated. REMS programs may impose additional provider and site certification requirements at the point of care. DEA rescheduling rulemaking typically occurs 90–180 days post-FDA approval and is a prerequisite to commercial prescribing.	KetamineLegal off-label Rx ✓ Spravato (esketamine)FDA approved 2019; REMS required ✓ COMP360 (psilocybin)Rolling NDA underway; final submission Q4 2026; CNPV awarded; commercial launch expected H1 2027 MDMA — Resilient PharmaceuticalsNDA resubmitted Aug 2026; no new Phase 3; FDA review outcome unknown Psilocybin (state)Oregon operational; Colorado operational; New Mexico Medical Psilocybin Act signed April 2025 — producer permits open Aug 2026; first patients targeted end of 2026
↓ unlocks coding layer
02	Gate 2 Language Medical Coding	Medical coding translates clinical services into the standardized language insurers use to adjudicate claims. Without appropriate CPT, HCPCS, or ICD-10 codes, services generally cannot be submitted or reimbursed through conventional insurance billing systems. Category III CPT codes track emerging procedures but carry no CMS-assigned RVUs. Reimbursement may occur but is set individually by each payor, with no standardized national floor.	0820T–0822TCat III psychedelic monitoring codes active Jan 2024 ✓ 90834 / 90837Psychotherapy codes available for prep and integration ✓ Cat III → Cat IRequires utilization data + AMA CPT panel application; triggers RVU assignment E/M codes99212–99215 for prescriber medical oversight during session (physicians, NPs, PAs only)
↓ unlocks coverage determination
03	Gate 3 Policy Coverage	Coverage determination is the payor's formal ruling on whether a service is a covered benefit. Insurers issue a coverage or medical policy defining medical necessity criteria and prior authorization requirements. For Medicare, this occurs through Local Coverage Determinations (LCDs) issued by Medicare Administrative Contractors. Broad commercial and Medicaid coverage for psychedelics is unlikely until federal DEA rescheduling occurs. Employer-sponsored benefits and state programs are the near-term pathway.	SpravatoBCBS, Aetna, UHC, Cigna, Medicare Part B; prior auth + TRD/MDD-SI diagnosis required ✓ Enthea TPAEmployer-sponsored KAP benefit; first psilocybin coverage in Oregon (April 2025) ✓ OON SuperbillPartial reimbursement for psychotherapy/integration; drug component generally not reimbursable OON Medicaid / CommercialPending federal rescheduling; real-world evidence from OR/CO programs is the primary lever LCD / NCD pathwayMedicare coverage determination mechanism once Cat I codes and RVUs are assigned
↓ unlocks standardized payment
04	Gate 4 Money Reimbursement	Reimbursement translates coverage policy into actual payment. RVUs determine Medicare rates and influence commercial fee schedules. Without favorable RVU valuation, a covered benefit may still be economically unviable to provide. Commercial insurers may reference RVUs but often set independent rates. (wRVU + PE RVU + MP RVU) × GPCI × Conversion Factor = Medicare Rate. Category III codes carry no RVUs; Cat I conversion is required for a standardized national rate.	SpravatoDual drug + monitoring billing model; widely covered by major commercial insurers ✓ Cat III codesNo CMS-assigned RVUs; each payor sets its own rate independently Cat I pathwayCat I application → RUC valuation → CMS Physician Fee Schedule inclusion Early reimbursementPsychotherapy and E/M codes can support partial billing before Cat I codes are established Claim formsCMS-1500 (professional services) / UB-04 (facility billing)

Provider Infrastructure — Network Participation

Step 01

Credentialing

Payor verification of licensure, training, and malpractice. Required before any network relationship can form.

State license verification

DEA registration

Malpractice & board certification

CAQH ProView profile & attestation

Psychedelic-specific training docs (emerging)

Set and setting

Step 02

Enrollment

Formal registration with each payor to receive payment. A provider can be credentialed but not yet enrolled, meaning not yet billable.

NPI Type 1 (individual clinician)

NPI Type 2 (organization)

Medicare / Medicaid PECOS enrollment

Commercial payor applications

TPA network enrollment (e.g. Enthea)

Step 03

Contracting

Executed payor agreements defining rates, claim requirements, and covered procedures. Provider Agreement → Rates → Panel Listing.

Provider agreement execution

Reimbursement rate negotiation

Practitioner panel listing / approval

Ongoing compliance & re-credentialing

Medical Coding Architecture

Code Type	Function	Psychedelic-Relevant Examples	Pathway Note
ICD-10 Diagnosis	Describes why the patient needs treatment. Must support medical necessity for the CPT service billed. Payor policy dictates which diagnoses qualify.	F33.2 — Major Depressive Disorder, Severe F43.10 — PTSD, Unspecified F10–F19 — Substance Use Disorders F31.x — Bipolar Disorder	Payor coverage policies will define qualifying diagnoses for each approved therapy.
CPT Procedure	Describes what was done. Category III codes exist for utilization tracking; Category I required for standardized national reimbursement with assigned RVUs.	Category III — Psychedelic Medication Therapy 0820T — Primary clinician monitoring (per 60 min) 0821T — Additional qualified HCP 0822T — Clinical staff support Supporting codes 90834 / 90837 — Psychotherapy (integration) +90785 — Interactive complexity add-on (complicating factors present) Codes 0820T–0822T submitted to AMA CPT Panel (Feb 2023) by Compass Pathways and MAPS PBC. BrainFutures published the field's primary coding guide (2023) and advocates for Cat I conversion.	Cat III → Cat I requires AMA application and utilization data. AMA CPT Editorial Panel meets 3× per year; Cat III codes valid 5 years before archival review.
RVU Valuation	The currency of physician payment. Only assigned by CMS when a Category I code exists. No RVU means no standardized national payment rate.	wRVU — Physician work component PE RVU — Practice expense (facility/staff/equipment) MP RVU — Malpractice component GPCI — Geographic Practice Cost Index	Category III carries no RVUs. Even after FDA approval of COMP360, standardized payment would require Cat I conversion, RUC valuation, and CMS fee schedule inclusion, typically 1–2 years post-approval.

Leading Indicator

Esketamine as the proof of concept, and the warning

Spravato (esketamine) was FDA-approved in 2019 for treatment-resistant depression and established the dual-payment template that psychedelic therapies will follow: drug administration codes billed separately from clinical monitoring codes. BCBS, Aetna, UHC, Cigna, Medicare Part B, and most state Medicaid programs now cover it, subject to prior authorization and REMS participation, demonstrating that the five-gate model works end-to-end. The Spravato WithMe access program shows how manufacturer support can accelerate insurer adoption.

But Spravato also illustrates a critical timing gap. If Compass Pathways receives FDA approval for COMP360 (psilocybin) in late 2026 or early 2027, that approval alone will not produce standardized reimbursement. The existing 0820T–0822T codes are Category III and carry no CMS-assigned RVUs. A Category I application would still need to be filed, evaluated by the AMA RUC, and incorporated into the CMS Physician Fee Schedule. That process typically takes one to two additional years. FDA approval is Gate 1. Payment requires all five gates.

Reimbursement Trajectory

2019–2023

Foundations

Spravato approved. Ketamine off-label expands. Compass + MAPS PBC submit 0820T–0822T to AMA (Feb 2023). BrainFutures coding guide published.

2024–2026

Evidence Builds

Cat III codes accumulate utilization data. Oregon and Colorado publish real-world outcomes. Compass Phase 3 complete; rolling NDA underway; CNPV awarded. Enthea TPA scales; first psilocybin coverage in Oregon (April 2025).

Late 2026–2027

First MDMA or Psilocybin Approval

Compass final NDA submission Q4 2026; CNPV shortens review; commercial launch expected H1 2027. Resilient Pharmaceuticals MDMA resubmission under FDA review. If either approved: DEA rescheduling required (90–180 days), Cat I CPT application filed, payor LCDs drafted. No RVU assigned at point of approval.

2028+

Mainstream Coverage

Cat I codes issued. RUC valuation → CMS Physician Fee Schedule. Commercial payors issue positive LCDs. Manufacturer access programs activate. Credentialed, contracted clinics bill first.

Sources: AMA CPT Editorial Panel · CMS Physician Fee Schedule · BrainFutures Guide to CPT and HCPCS Codes for Psychedelic-Assisted Therapy (2023) · Compass Pathways investor disclosures (Feb 2026) · Oregon Health Authority quarterly data dashboard · Enthea network documentation · MAPS / Lykos Therapeutics regulatory filings.
Category III CPT codes 0820T–0822T effective January 2024; valid 5 years before AMA archival review. Compass CNPV awarded April 2026; final NDA submission Q4 2026. Resilient Pharmaceuticals (formerly Lykos) resubmitted MDMA NDA August 2026 as Rysanso; FDA outcome pending. DEA rescheduling typically 90–180 days post-FDA approval.

The Road toReimbursement

The Road to
Reimbursement